Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HAELO: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2002 in Participants With Hereditary Angioedema (HAE)

NCT06634420 is registered in ClinicalTrials.gov with Intellia Therapeutics as lead sponsor.

NCT NCT06634420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06634420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HAELO: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2002 in Participants With Hereditary Angioedema (HAE)
Lead sponsor
Intellia Therapeutics
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 15, 2025
Completion date
September 30, 2027
Enrollment
80 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema